China Scar Treatment Market To Surpass US$ 5,317.7 Million By 2027
China Scar Treatment Market To Surpass US$ 5,317.7 Million By 2027

Burn injury or other traumacondition, including surgery can lead to a scar. Several factors impact theappearance and treatment of scar after an injury. Topical Scar Treatment, LaserTreatment, and Invasive Surgical Treatment are some of the options for scartenement.

ChinaScar Treatment Market is estimated to account for US$ 2,422.5 Mn in termsof value by the end of 2019.

China Scar Treatment Market:Drivers

Increasing aesthetic appeal amongthe populace in China is expected to boost growth of China scar treatmentmarket. Moreover, increasing product launch and assessment is also expected toboost growth of the market over the forecast period. For instance, in June2019, AVITA Medical, a regenerative medicine company, announced new preliminaryRECELL Autologous Cell Harvesting Device (RECELL System) data at the 24thannual World Congress of Dermatology Meeting. The RECELL system is used in thetreatment of vitiligo and facial acne scars.

China Scar Treatment Market:Opportunities

Increasing R&D in skin defectreconstruction is expected to offer lucrative growth opportunities for marketplayers over the forecast period. For instance, in August 2019, researchersfrom Naval Medical University, China, reported that use of mincedsplit-thickness skin grafts with Pelnac as an overlay can be effective inreconstruction of full-thickness skin defects.

China Scar Treatment Market:Restraints

Stringent regulations in Chinaare expected to hamper growth of the market. China has complicated andstringent regulatory requirements. It requires over 18 months to gain marketaccess in the country.

Key Takeaways:

The Aesthetic Lasers segment inthe China scar treatment market was valued at US$ 1,119.8 Mn in 2018 and isexpected to reach US$ 2,717.3 Mn by 2027 at a CAGR of 10.4% during the forecastperiod. The growth of the segment is attributed to increasing number ofaesthetic surgical procedures in the country

The laser treatment segment helddominant position in China scar treatment market in 2018, accounting for 45%share in terms of volume, followed by topical treatment and invasive surgicaltreatment, respectively. The growth of the segment is attributed to increasingdemand for non-invasive surgical procedures.

* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copyof this report:

Market Trends

The demand for over-the-countercosmetic laser and light devices has increased in the recent past. These homeuse devices use various technologies such as intense pulsed light (IPL) andlight-emitting diodes (LED).

Cosmetic or plastic surgery andother scar treatment and related products are available at a very affordableprice in China. This can be attributed to high competitiveness among marketplayers.


The market is regulated byChina’s Good Manufacturing Practices and FDA.

Manufacturer needs to establish aquality management system as China’s FDA guidelines to maintain productconsistency and quality throughout

Manufacturer are required tostrictly implement GMP with integrity without any falsification

Measurability of quality,consistency and efficacy needs to be well documented to ensurepharmacovigilance

Browse ResearchReport:

Sampling, manufacturing, anddevelopment of drugs should only be carried out by trained personnel

Location, design, layout,construction, adaption and maintenance of premises should suit the drugproduction requirements and minimize risk of contamination

China Scar Treatment Market:Competitive Landscape

Major players operating in Chinascar treatment market include, Cynosure, Inc., Syneron Medical Ltd., MölnlyckeHealth Care, Ostar Beauty Sci-Tech Co., Ltd., Shanghai Fosun Pharmaceutical Co.Ltd., Beijing Toplaser Technology Co., Ltd., Merz Pharma, and Luca Pharmaceuticals.

Key Developments

Key players in the market arefocused on adopting inorganic growth strategies to expand their productportfolio. For instance, in November 2019, AVITA Medical collaborated with theGates Center for Regenerative Medicine at the University Of Colorado School OfMedicine to establish proof-of-concept and explore further development of aspray-on treatment of genetically modified cells for patients withepidermolysis bullosa (EB) and other genetic skin disorders.

In December 2019, JanssenBiotech, Inc. entered a definitive agreement to acquire all rights to theinvestigational compound bermekimab – an anti-IL-1alpha monoclonal antibody forthe treatment of atopic dermatitis and hidradenitis suppurativa— from XBiotechInc.

Buy-Now this researchreport:

AboutCoherent Market Insights:            

CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.



Name:  Mr. Shah

CoherentMarket Insights 1001 4th Ave,

# 3200Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737